Keywords: AE; ALT; BMI; BOC; BT; CPGs; CYP3A4; Clinical Practice Guidelines; DAA; DVR; EIA; EPO; EVR; G-CSF; GRADE; Grading of Recommendations Assessment, Development and Evaluation; HBV; HCC; HCV; IDU; IFN; IU; LSM; LT; OST; PI; PWID; PegIFN/RBV; RVR; SCAR; SVR; TSH; TVR; adverse event; alanine aminotransferase; boceprevir; body mass index; cytochrome p450 3A4; delayed virological response; direct-acting antiviral; eRVR; early virological response; enzyme immunoassays; erythropoietin; extended rapid virological response; granulocyte colony stimulating factor; hepatitis B virus; hepatitis C virus; hepatocellular carcinoma; interferon; international units; intravenous/injecting drug use; liver stiffness measurement; liver transplant; opiate/opioid substitution treatment/therapy; pegylated interferon-α and ribavirin; people who inject drugs; protease inhibitor; rapid virological response; severe cutaneous adverse reaction; sustained virological response; telaprevir; thyroid stimulating hormone; viral breakthrough.